2nd Medical Affairs & Rare Disease
West Coast

Cross-Functional Collaboration in Rare Disease:
Breaking Down Silos to Identify Solutions

August 24-25, 2020

Online LIVE Stream

Event Overview

The new coronavirus has paralyzed our world, but older diseases remain as dangerous as ever.  Rare disease patient needs have become even more challenging in an age of social distancing and fears of contagion.

To help serve the patients who are under the most risk and are least able to wait for society to reopen, Dynamic Global Events invites you to participate in the 2nd annual Medical Affairs & Rare Disease – West Coast conference – this year held entirely streaming online.  At a time when people are forced to stay apart, this forum helps you unite multi-stakeholder teams across functions, organizations, and therapeutic areas, in order to solve problems and identify rare disease solutions.

About the Chairperson

Image

Dr. Matthew T. Roe has been a faculty member at Duke University School of Medine and the Duke Clinical Research Institute (DCRI) since 1999. As a senior investigator at the DCRI, he has been the principal investigator for numerous phase II-IV cardiovascular clinical trials and is currently a co-principal investigator for the ADAPTABLE trial—the first large-scale pragmatic trials being conducted in the PCORnet network. He has also served in leadership roles for several observational registries focusing upon the treatment and outcomes of patients with cardiovascular disease and has served as the Director of the DCRI Clinical Research Fellowship since 2010.

Featured Speakers

Image

Craig Lipset

Head of Clinical Innovation
Pfizer

Image

Jeff Kingsley

Chief Executive Officer
IACT Health 

Image

Dawn Anderson

Managing Director, Life Sciences Strategy and Operations, R&D Practice
Deloitte

Image

Ross Friedberg

General Counsel & Chief Privacy Officer
Doctor on Demand

Top Reasons to Attend

  1. Maps for adapting rare disease development and outreach to a post-COVID world
  2. Detailed strategies for ensuring patient centricity in rare disease clinical trials
  3. Tools for spotting and avoiding the most urgent mistakes that can strike a rare disease program
  4. Insights for building and learning from cross-disciplinary teams
  5. New visions for the medical affairs must-haves for both small and large pharma

Attendee Profile

This conference is designed for senior leaders and executives in pharmaceutical, biotech, and medical device companies responsible for:

  • Rare Disease
  • Orphan Drugs
  • Gene Therapy
  • Medical Affairs
  • Medical Messaging
  • MSL
  • Clinical Affairs
  • Patient Affairs
  • Patient Outreach
  • Patient Engagement
  • Patient Advocacy
  • Medical Publication Planning
  • eClinical
  • Health Economics & Outcomes Research

Monday

August 24th, 2020 | Day 1

9:00 AM

Login

9:00 AM - 9:15 AM

Conference Opening Remarks

9:15 AM - 10:00 AM

Creating Strategic Plans for Cross Functional Collaboration and Growth

Andy Overmyer, Head of Global Business Operations
AKCEA THERAPEUTICS

10:00 AM - 10:45 AM

Medical Affairs Do’s and Don’ts – Transitioning from a Small Biotech to a Large Biopharma Company

Oscar Seguardo, MD, Ph.D - Chief Medical Officer
ASC THERAPEUTICS

10:45 AM - 11:00 AM

Break

11:00 AM - 12:00 PM

Collaborative Private/Public Partnerships for Real World Evidence Collection and Expanded Access to Rare Disease Therapies

Wendy White - Chairman
GLOBAL GENES and Co-Founder, RAREITI

Natalie Douglas - Vice Chairman
GLOBAL GENES and Co-Founder, RAREITI

12:00 PM - 1:00 PM

Networking Lunch

1:00 PM - 1:45 PM

Collaborating Around Rare Disease

Jon Kaskey - Regional Vice President, Business Partnerships
WITHIN3

1:45 PM - 2:45 PM

PANEL: Rare Disease Clinical Research: Literacy, Diversity, Engagement, Technology and Retention

Joan A. Chambers - Senior Director, Marketing and Outreach
CENTER FOR INFORMATION & STUDY ON CLINICAL RESEARCH PARTICIPATION (CISCRP)

Harsha Rajasimha, MS, Ph.D - Founder and Chairman
INDOUSRARE

2:45 PM - 3:00 PM

Break

3:00 PM - 3:45 PM

Building a Small Pharma Rare Disease Strategy that Avoids the Classic Obstacles to Drug Approval

Drug companies often don’t understand enough about the full preparation for rare disease drug approval, and this can be especially troublesome for small companies.  Often there is no sustainable or steady strategy, as projects change in multiple direction based on advice or requests from the board of directors.  How can you best plan for the finish line when you’re just getting started?  

  • Spot the warning signs of opening or closing too many studies
  • Avoid carrying out key steps in the improper order
  • Build a team culture of properly visualizing the goal from the outset

May Orfali - Chief Medical Officer
BIOASIS TECHNOLOGIES

Tuesday

August 25th, 2020 | Day 2

9:00 AM

Login

9:00 AM - 9:15 AM

Recap of Day 1 & Day 2 Opening Remarks

9:15 AM - 10:00 AM

Improve Commercial and Medical Affairs Teamwork when Advancing Pediatric Rare Disease Therapies

Commercial, medical affairs, and medical communications teams must be closely involved from the earliest stages in order to accurately guide sales. This is especially true for rare disease therapeutics for which doctors might see only one patient per month at the most. The entire clinical and medical affairs management cycles for rare disease will have to significantly change in response to the COVID-19 pandemic.

  • Pinpoint the medical affairs and communication partnerships and messaging most essential in new APDS therapeutics
  • Track the key steps in expanding rare disease therapeutics for a new pediatric indication
  • Adapt your methods and messaging to a post-coronavirus world

Colin Scott - Executive Medical Director
PHARMING

10:00 AM - 10:45 AM

Deploy Medical Affairs Expertise for Vital Information Gathering to Improve Trial Patient-Centricity and Success

The patient voice must move to the forefront of clinical trial planning, or else you are at risk of missed endpoints, low enrollment, and wasted time and money.  Dedicated MSL teams can be powerful tools for gathering patient information and, in turn, properly structuring your trials.  With their direct access to the patient voice, they are also vital in educating clinical staff about the disease. 

  • Reorient logistics, consent forms, and follow-ups around the patient voice
  • Rely on medical affairs professionals to verify your assumptions about age spread and disease severity
  • Strengthen advisory board meetings through medical affairs input

Barbara Wuebbels - Chairman
PROFESSIONAL PATIENT ADVOCATES IN LIFE SCIENCE

10:45 AM - 11:00 AM

Break

11:00 AM - 11:45 AM

Top Challenges for Rare Disease Patients and Caregivers that Medical Affairs Practitioners May Overlook

Christine von Raesfeld - Founder/CEO
PEOPLE WITH EMPATHY

11:45 AM - 12:30 PM

Sponsored Presentation by H1 INSIGHTS

Robert Consalvo - Director of Strategic Commercial Engagement
H1 INSIGHTS

12:30 AM - 1:30 PM

Lunch

1:30 PM - 2:15 PM

Leading New Collaborative Initiatives to Center the Patient Experience

Sarah Krug - Executive Director
CANCER 101

2:15 PM - 4:15 PM

CASE STUDY PRACTICUM: Best Practices for Breaking Down Silos to Identify Solutions

  • Actionable Implications to Achieve Clinical Development, Product Launch Goals,
    Drug Safety and Favorable Outcomes
  • Building High-performing Multi-stakeholder Teams
  • Leading Internal Project Teams Across Functions, Geographies and Therapeutic
    Areas
  • Collaborating Across Organizations -- Science, Business and Non-profits

Thomas Lester - Executive Director Program Management
AUDENTES THERAPEUTICS

Steven G. Rizk, PharmD, JD - Senior Director - Medical Strategy
RYPE HEALTH

FEATURED SPEAKERS

Image

Oscar Segurado

ASC Therapeutics

Chief Medical Officer

Image

Joan A. Chambers

The Center for Information & Study on Clinical Research Participation (CISCRP)

Senior Director, Marketing & Outreach

Image

Michael Forstner

PrimeVigilance

Senior Vice President and Head of Pharmacoepidemiology and Risk Management

Image

Sheila Bose

SB Lifesciences Consulting, Inc

President

Image

Christine Von Raesfeld

PEOPLE WITH EMPATHY

Founder / CEO

Image

Angela Ramirez Holmes

Cal Rare

Founder/President

Image

Tom Lester

Audentes Therapeutics

Executive Director Program Management

Image

Steven G. Rizk

Rype Health

Senior Director Medical Strategy

Image

Maureen McArthur Hart

Global Genes

Director, Research

Image

Andy Overmyer

Akcea Therapeutics

Head of Global Business Operations

Image

Wendy White

GLOBAL GENES

Chairman

Co-Founder, RAREITI

Image

Natalie Douglas

GLOBAL GENES

Vice Chairman

Co-Founder, RAREITI

Image

Harsha K. Rajasimha

INDOUSRARE

Founder and Chairman

Founder Chairman, Indo US Organization for Rare Diseases

Image

Sarah Krug

CANCER 101

Executive Director

Image

May Orfali

BIOASIS TECHNOLOGIES

Chief Medical Officer

Image

Colin Scott

PHARMING

Executive Medical Director

Image

Barbara Wuebbels

PROFESSIONAL PATIENT ADVOCATES IN LIFE SCIENCE

Chairman

CONFERENCE REGISTRATION


LIVE STREAM PRICING

STANDARD

Register Anytime

$896

Interested in registering groups of 10 or more? Contact us directly for pricing.

EVENT SPONSORS


Within3 - Proud Sponsor

PREMIER MEDIA PARTNER

Scarritt Group - Official Media Partner

OFFICIAL LIVESTREAM PROVIDER


SPONSOR THIS EVENT

Contact Amy Chapman at (561) 571-7687 or achapman@dgeconfs.com

MEDIA PARTNERS


PM360 - Media Partner

PREMIER MEDIA PARTNER


MEDIA PARTNERS

Image

PREMIER MEDIA PARTNER